Knockdown of SCARA5 inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration through suppression of the PDGF signaling pathway

Zhao,Jiangtao; Jian,Liguo; Zhang,Lihua; Ding,Tongbin; Li,Xiaowei; Cheng,Dong; Niu,Shaohui; Sun,Liqiang; Li,En; Liu,Shichao; Jiang,Youxu; Liu,Lu

doi:10.3892/mmr.2016.5074

Knockdown of SCARA5 inhibits PDGF-BB-induced vascular smooth muscle cell proliferation and migration through suppression of the PDGF signaling pathway

Authors:
- Jiangtao Zhao
- Liguo Jian
- Lihua Zhang
- Tongbin Ding
- Xiaowei Li
- Dong Cheng
- Shaohui Niu
- Liqiang Sun
- En Li
- Shichao Liu
- Youxu Jiang
- Lu Liu
View Affiliations

Affiliations: The Second Ward of Cardiovascular Department, The Second Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China, Department of Nephrology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan 450000, P.R. China
Published online on: March 30, 2016 https://doi.org/10.3892/mmr.2016.5074
Pages: 4455-4460

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Vascular smooth muscle cell (VSMC) proliferation and migration are critical in the progression of atherosclerosis and can be induced by platelet-derived growth factor (PDGF). Several studies have demonstrated that scavenger receptor class A, member 5 (SCARA5) is important in cancer cell migration and invasion. However, the role of SCARA5 in VSMCs remains to be elucidated in the development of atherosclerosis. Therefore, the role of SCARA5 was investigated in PDGF‑BB‑stimulated VSMC proliferation and migration. In the present study, it was shown that SCARA5 expression was enhanced by PDGF‑BB in human aortic smooth muscle cells (HASMCs). Knockdown of SCARA5 by small interfering (si)RNA significantly inhibited PDGF‑BB‑induced HASMC proliferation and migration. Furthermore, siRNA‑SCARA5 significantly inhibited the phosphorylation of PDGF receptor (PDGFR) β, AKT and extracellular signal‑regulated kinase 1/2 in PDGF‑BB‑stimulated HASMCs. In conclusion, this study demonstrated that knockdown of SCARA5 inhibits PDGF‑BB‑induced HASMC proliferation and migration through suppression of the PDGF signaling pathway. Thus, SCARA5 may be a novel therapeutic target for preventing or treating vascular diseases involving VSMC proliferation and migration.

View Figures

View References

1	Ross R and Agius L: The process of atherogenesis-cellular and molecular interaction: From experimental animal models to humans. Diabetologia. 35(Suppl 2): S34–S40. 1992. View Article : Google Scholar
2	Wang JC and Bennett M: Aging and atherosclerosis: Mechanisms, functional consequences and potential therapeutics for cellular senescence. Circ Res. 111:245–259. 2012. View Article : Google Scholar : PubMed/NCBI
3	Ross R: Atherosclerosis-an inflammatory disease. New Engl J Med. 340:115–126. 1999. View Article : Google Scholar
4	Owens GK: Regulation of differentiation of vascular smooth muscle cells. Physiol Rev. 75:487–517. 1995.PubMed/NCBI
5	Heldin CH and Westermark B: Mechanism of action and in vivo role of platelet-derived growth factor. Physiol Rev. 79:1283–1316. 1999.PubMed/NCBI
6	Peiser L and Gordon S: The function of scavenger receptors expressed by macrophages and their role in the regulation of inflammation. Microbes Infect. 3:149–159. 2001. View Article : Google Scholar : PubMed/NCBI
7	Whelan FJ, Meehan CJ, Golding GB, McConkey BJ and Bowdish DM: The evolution of the class A scavenger receptors. BMC Evol Biol. 12:227–237. 2012. View Article : Google Scholar : PubMed/NCBI
8	Liu J, Hu G, Chen D, Gong AY, Soori GS, Dobleman TJ and Chen XM: Suppression of SCARA5 by Snail1 is essential for EMT-associated cell migration of A549 cells. Oncogenesis. 2:e732013. View Article : Google Scholar : PubMed/NCBI
9	Yan N, Zhang S, Yang Y, Cheng L, Li C, Dai L, Dai L, Zhang X, Fan P, Tian H, et al: Therapeutic upregulation of Class A scavenger receptor member 5 inhibits tumor growth and metastasis. Cancer Sci. 103:1631–1639. 2012. View Article : Google Scholar : PubMed/NCBI
10	Huang J, Zheng DL, Qin FS, Cheng N, Chen H, Wan BB, Wang YP, Xiao HS and Han ZG: Genetic and epigenetic silencing of SCARA5 may contribute to human hepatocellular carcinoma by activating FAK signaling. J Clin Invest. 120:223–241. 2010. View Article : Google Scholar :
11	Auclair S, Milenkovic D, Besson C, Chauvet S, Gueux E, Morand C, Mazur A and Scalbert A: Catechin reduces atherosclerotic lesion development in apo E-deficient mice: A transcriptomic study. Atherosclerosis. 204:e21–e27. 2009. View Article : Google Scholar : PubMed/NCBI
12	Chadjichristos CE, Morel S, Derouette JP, Sutter E, Roth I, Brisset AC, Bochaton-Piallat ML and Kwak BR: Targeting connexin 43 prevents platelet-derived growth factor-BB-induced phenotypic change in porcine coronary artery smooth muscle cells. Circ Res. 102:653–660. 2008. View Article : Google Scholar : PubMed/NCBI
13	Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 25:402–408. 2001. View Article : Google Scholar
14	Andrés V: Control of vascular cell proliferation and migration by cyclin-dependent kinase signalling: New perspectives and therapeutic potential. Cardiovasc Res. 63:11–21. 2004. View Article : Google Scholar : PubMed/NCBI
15	Syväranta S, Alanne-Kinnunen M, Oörni K, Oksjoki R, Kupari M, Kovanen PT and Helske-Suihko S: Potential pathological roles for oxidized low-density lipoprotein and scavenger receptors SR-AI, CD36 and LOX-1 in aortic valve stenosis. Atherosclerosis. 235:398–407. 2014. View Article : Google Scholar
16	Raines EW: PDGF and cardiovascular disease. Cytokine Growth Factor Rev. 15:237–254. 2004. View Article : Google Scholar : PubMed/NCBI
17	Abe J, Deguchi J, Takuwa Y, Hara K, Ikari Y, Tamura T, Ohno M and Kurokawa K: Tyrosine phosphorylation of platelet derived growth factor beta receptors in coronary artery lesions: Implications for vascular remodelling after directional coronary atherectomy and unstable angina pectoris. Heart. 79:400–406. 1998. View Article : Google Scholar : PubMed/NCBI
18	Jawien A, Bowen-Pope DF, Lindner V, Schwartz SM and Clowes AW: Platelet-derived growth factor promotes smooth muscle migration and intimal thickening in a rat model of balloon angioplasty. J Clin Invest. 89:507–511. 1992. View Article : Google Scholar : PubMed/NCBI
19	Bilder G, Wentz T, Leadley R, Amin D, Byan L, O'Conner B, Needle S, Galczenski H, Bostwick J, Kasiewski C, et al: Restenosis following angioplasty in the swine coronary artery is inhibited by an orally active PDGF-receptor tyrosine kinase inhibitor, RPR101511A. Circulation. 99:3292–3299. 1999. View Article : Google Scholar : PubMed/NCBI
20	Lannoy M, Slove S, Louedec L, Choqueux C, Journé C, Michel JB and Jacob MP: Inhibition of ERK1/2 phosphorylation: A new strategy to stimulate elastogenesis in the aorta. Hypertension. 64:423–430. 2014. View Article : Google Scholar : PubMed/NCBI
21	Mii S, Khalil RA, Morgan K, Ware JA and Kent KC: Mitogen-activated protein kinase and proliferation of human vascular smooth muscle cells. Am J Physiol. 270:H142–H150. 1996.PubMed/NCBI
22	Nomiyama T, Nakamachi T, Gizard F, Heywood EB, Jones KL, Ohkura N, Kawamori R, Conneely OM and Bruemmer D: The NR4A orphan nuclear receptor NOR1 is induced by platelet-derived growth factor and mediates vascular smooth muscle cell proliferation. J Biol Chem. 281:33467–33476. 2006. View Article : Google Scholar : PubMed/NCBI
23	Goncharova EA, Ammit AJ, Irani C, Carroll RG, Eszterhas AJ, Panettieri RA and Krymskaya VP: PI3K is required for proliferation and migration of human pulmonary vascular smooth muscle cells. Am J Physiol Lung Cell Mol Physiol. 283:L354–L363. 2002. View Article : Google Scholar : PubMed/NCBI
24	Choi KH, Kim JE, Song NR, Son JE, Hwang MK, Byun S, Kim JH, Lee KW and Lee HJ: Phosphoinositide 3-kinase is a novel target of piceatannol for inhibiting PDGF-BB-induced proliferation and migration in human aortic smooth muscle cells. Cardiovasc Res. 85:836–844. 2010. View Article : Google Scholar
25	Lipson KE, Pang L, Huber LJ, Chen H, Tsai JM, Hirth P, Gazit A, Levitzki A and McMahon G: Inhibition of platelet-derived growth factor and epidermal growth factor receptor signaling events after treatment of cells with specific synthetic inhibitors of tyrosine kinase phosphorylation. J Pharmacol Exp Ther. 285:844–852. 1998.PubMed/NCBI
26	Myllärniemi M, Frösen J, Ramirez LG, Buchdunger E, Lemström K and Häyry P: Selective tyrosine kinase inhibitor for the platelet-derived growth factor receptor in vitro inhibits smooth muscle cell proliferation after reinjury of arterial intima in vivo. Cardiovasc Drug Ther. 13:159–168. 1999. View Article : Google Scholar